About Curida
Curida is a company based in Elverum (Norway) founded in 2015. Curida has raised $3.2 million across 2 funding rounds from investors including Signet Healthcare Partners and Investinor. The company has 65 employees as of December 31, 2018. Curida offers products and services including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services. Curida operates in a competitive market with competitors including Crown Laboratories, Encube Ethicals, Famar, Formulated Solutions and Contract Pharmaceuticals, among others.
- Headquarter Elverum, Norway
- Employees 65 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$20.69 M (USD)47as on Dec 31, 2022
-
Net Profit
-$4.78 M (USD)-186as on Dec 31, 2022
-
EBITDA
-$3 M (USD)-511as on Dec 31, 2022
-
Total Equity Funding
$3.2 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
Signet Healthcare Partners
& 1 more
-
Employee Count
65
as on Dec 31, 2018
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curida
Curida offers a comprehensive portfolio of products and services, including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Develops formulations for safe medicine supply and manufacturing.
Produces liquid drugs using blow-fill-seal technology for sterile products.
Specializes in monoclonal antibodies production and conjugation services.
Provides raw materials and special pharmaceuticals for pharmacies.
People of Curida
Unlock access to complete
Unlock access to complete
Funding Insights of Curida
Curida has successfully raised a total of $3.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(01 Jan 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Seed - Curida | Valuation |
investors |
|
| Jan, 2018 | Amount | Seed - Curida | Valuation |
investors |
Investors in Curida
Curida has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Signet Healthcare Partners and Investinor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in North America and Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Curida
Financial Statements - Curida
Curida Comparisons
Competitors of Curida
Curida operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Crown Laboratories, Encube Ethicals, Famar, Formulated Solutions and Contract Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
OTC, prescription, skin care, and oral care products are manufactured.
|
|
| domain | founded_year | HQ Location |
Contract development and manufacturing for topical semisolid formulations are provided.
|
|
| domain | founded_year | HQ Location |
Contract manufacturing and development services provider
|
|
| domain | founded_year | HQ Location |
Company offering CDMO services for the pharma (Rx and OTC), medical device, personal care and veterinary medicine sectors
|
|
| domain | founded_year | HQ Location |
CDMO focused on manufacturing of semi-solid pharmaceutical drugs
|
Latest news on Curida
Frequently Asked Questions about Curida
Curida was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Curida is headquartered in Elverum, Norway.
Curida is a funded company, having raised a total of $3.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3.2M, raised on Jan 01, 2018.
As of Dec 31, 2018, the latest employee count at Curida is 65.
Annual revenue of Curida is $20.69M as on Dec 31, 2022.
Curida is a CDMO offering its services for the development of iquid dosage forms in formats such as blow fill seals, nasal sprays and bottles. More than 90 of Curidas revenues comes from their exports to 30 countries and they claim to have 40 years of experience in this field. Their development services portfolio includes formulation development, analytical method development and validation, stability studies, tech transfer and regulatory support. Curidas development services cater mainly to the development of nasal and inhalation drug products (OINDP) and other ophthalmic or topical products which are usually administered with the help of a delivery device.
Curida's top competitors include Encube Ethicals, Famar and Crown Laboratories.
Curida offers Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Curida has 2 investors. Key investors include Signet Healthcare Partners, and Investinor.